The efficacy of hyperbaric oxygen on electrocardiographic abnormalities in patients exposed to high altitude: an open-label, randomized, crossover, controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043300

Enrollment

Unknown

Registered

2021-02-09

Start date

2021-02-10

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high altitude induced electrocardiographic abnormalities

Interventions

Hyperbaric Oxygen:Hyperbaric Oxygen Treatment

Control group:no intervention

Masked oxygen:Masked oxygen 3L/min

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. ascend to high altitude (over > 3500m) for at least 3 months, and not return to lowland in 1 month; 3. ECG test with one of the following signs QRS Right Axis Deviation (over 95 degree); 4. written consent. 5. no contraindications to hyperbaric oxygen treatment.

Exclusion criteria

Exclusion criteria: 1. Contraindication of hyperbaric oxygen treatment; 2. critical conditions required to be transferred to lowland for further treatment. 3. with pulmonary diseases, arrhythmia, coronary heart diseases, cardiomyopathy.

Design outcomes

Primary

Measure	Time frame
12 lead ECG;	—

Secondary

Measure	Time frame
echocardiography;	—

Countries

China

Contacts

Public ContactZhexue Qin; Fan Yang

Dept. of Cardiology, Xinqiao Hospital; No.948 Hospital of the Army

zhexueqin@126.com+86 15823810730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026